Chandra Bhagat Pharma Limited IPO subscription period from Jan 31 to Feb 6, 2020:
Chandra Bhagat Pharma Limited launched in 2003. The company involved in the lifesaving medicines market in India. It produced medicines like Cardiovascular, Antineoplastic, Antibiotics and Hormone medicines. The company introduced a new IPO in Small and Medium-sized Enterprises (SME). The IPO subscription period will start on 31st Jan and it will end on 6th Feb 2020.
Chandra Bhagat Pharma Limited IPO Details:
| Bid Period | Jan 31 to Feb 6, 2020 |
| IPO Type | Fixed Price Issue |
| IPO Size | 2,000,000 Eq Shares of Rs 10 (aggregating up to Rs 10.20 cr) |
| Face Value | Rs 10 Per Eq Share |
| Issue Price | Rs 51 Per Eq Share |
| Market Lot | 2000 Shares |
| Min Order Quantity | 2000 Shares |
| Listing At | BSE SME |
It is a Fixed Price Issue type of IPO with the face value of Rs 10 per equity share. Initially, the size of the IPO is 2,000,000 equity shares of Rs 10 with aggregating up to Rs 10.20 crore. The offered price of the IPO is Rs 51 per equity share at the time of subscription. Moreover, the market Lot of the CBC Pharma IPO is 2000 shares. Also, the minimum order quantity is 2000 shares (1 lot) and the price of the lot is nearly Rs 102,000.
Promoter Holdings:
The promoters or lead managers of the company are Hemant Chandravadan Bhagat and Pranav Hemant Bhagat.
| Pre Issue Share Holding | 96.72% |
| Post Issue Share Holding | 71.08% |
The objective of the company, it plans to utilize the raised amount for the growth of working capital, to arrange distribution and warehousing centers, IPO expenses and general corporate purposes. The IPO will be listed on BSE SME on Feb 14, 2020. On 11th Feb, the allotment order will be issued.
Registrar:
Link Intime India Pvt Ltd
C 101, 247 Park, L.B.S.Marg,
Vikhroli (West), Mumbai – 400083
Phone: +91-22-4918 6270
Email: [email protected]
Website: http://www.linktime.co.in
Disclaimer: This post is just information about the IPO. It does not give any advice or recommendation. Please read the offer document carefully and consult your advisor before investing.
